Identify predictive blood signature for severe forms of Covid-19
Which patient will develop a severe form of Covid-19? Inserm researchers believe they can answer this question after discovering a unique and unexpected immune phenotype in critically ill and critically ill patients.
These are biomarkers that can be identified in the blood before the patient's health condition worsens.
The vast majority of people infected with coronavirus experience a mild form of Covid-19. However, among the patients examined so far, 15% require hospitalization and 5% will have to be admitted to intensive care for a serious form: these patients progress to a serious or critical form and, in particular, severe pneumonia that has become in acute respiratory distress.
If you are looking for a home visit, general studies describing a progress from back to back, there is a form, a guide to the breathing system from 9 to 12 from the beginning of the first symptoms closed
This sudden development suggests a dysregulation of the host's inflammatory response. As Inserm explains on this topic, a critical number of indications suggest that it is an increase in cytokines. "This runaway inflammatory response correlates with massive infiltration into the lungs of innate immune cells; neutrophils and monocytes, creating lung damage and acute respiratory distress syndrome. Initial hypotheses assume IFN production), a marker of response to infections, "the agency said.
A prognosis thanks to blood plasma?
This is an essential question that needs to be confirmed to improve individual care and prognosis for these patients. Otherwise, in a publication of the Science Magazine, researchers from various French institutes found that in severely confined patients, the production and activity of type I IFNs is greatly reduced in very severe forms of COVID-19.
"In addition, there is a persistent viral load in the blood, demonstrating poor control of viral replication by the patients' immune systems and causing excitation of an ineffective and pathological inflammatory response," the scientific team said.
Finally, the study also reveals that low levels of type 1 IFN in plasma (the liquid part of blood used to transport blood cells and hormones throughout the body) precede clinical treatment of patients and transport to intensive care. Circulating levels of type 1 IFN are characterized even at each stage of the disease: the lowest levels are seen in the most severe patients.
Therefore, these results detected in SARS-CoV-2 infection, the production of type IFN reduced the speed in the infected host, which could explain the more serious forms in people whose organism produces little this cytokine, such as older people. or with comorbidities. "Type I IFN deficiency could be a signature of severe forms of Covid-19 and could help identify a high-risk population." Create the scientific team. It is created to administer anti-inflammatory therapy or corticosteroids to the most serious patients. It could be Baroque to eradicate severe forms of Covid-19.